ADTX

Aditxt, Inc. operates as a biotech innovation company focused on developing technologies to modulate the immune system. Headquartered in Richmond, Virginia, the company concentrates on immune monitoring and therapeutic solutions designed to improve transplant outcomes and treat immune-related conditions. Aditxt's primary product platform includes Adimune, a therapeutic system intended to retrain the immune system to induce tolerance in organ transplant recipients, potentially reducing or eliminating the need for lifelong immunosuppressive drugs. The company also develops AditxtScore, a comprehensive immune profiling system that provides a personalized assessment of an individual's immune health through advanced biomarker analysis. As a clinical-stage company, Aditxt directs its research toward addressing significant unmet medical needs in transplantation and autoimmune diseases. The company has established research collaborations and pursued regulatory pathways to advance its technology platforms through clinical development. Aditxt went public through a merger with Engenic Holdings in 2020 and trades on the Nasdaq exchange. The company operates with a lean organizational structure typical of early-stage biotech firms, focusing resources on research and development activities. Aditxt's business model centers on developing proprietary immune monitoring and modulation technologies with potential applications across multiple therapeutic areas, positioning itself within the emerging field of immune tolerance and personalized medicine.